The Association of CYP1A1 rs1048943 PolymorphismA Comprehensive Meta-Analysis of Case Control Studies

Abstract

Breast cancer remains the most prevalent malignancy in women worldwide and its etiology involves genetic and environmental components. Among these genetic components, the CYP1A1 rs1048943 (Ile462Val) polymorphism has been shown to play a modifying role in breast cancer susceptibility based on its contribution to the metabolism of carcinogens and estrogens. This meta-analysis objectively estimated the risk association of this polymorphism and breast cancer in 34 case-control studies including 14,166 cases and 18,912 controls Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated under various genetic models. The dominant model (GG+GA vs. AA) revealed a significant association with breast cancer risk in the overall population (OR = 1.1533, 95% CI: 1.0038–1.3250, p = 0.044). Subgroup analysis by ethnicity showed a stronger effect in Asian populations (OR = 1.2742, 95% CI: 1.0123–1.6038, p = 0.039), while a protective effect was observed in Caucasians (OR = 0.8843, 95% CI: 0.7837–0.9979, p = 0.046). Other genetic models, including the allele contrast, recessive, over dominant, and homozygote comparisons, did not show statistically significant associations in the overall analysis. Sensitivity analyses confirmed the consistency of findings, stability of the dominant model results, and no major publication bias was detected. These findings suggest that the CYP1A1 rs1048943 polymorphism may be associated with breast cancer susceptibility, particularly among Asian populations, while ethnic differences may influence its effect.

Keywords

References

1. B. Luo, D. Yan, H. Yan, and J. Yuan, “Cytochrome P450: Implications for human breast cancer
2. (Review),” Oncol. Lett., vol. 22, no. 1, 2021, doi: 10.3892/ol.2021.12809.
3. S. Lei et al., “Global patterns of breast cancer incidence and mortality: A population-based cancer
4. registry data analysis from 2000 to 2020,” Cancer Commun., vol. 41, no. 11, pp. 1183–1194, 2021, doi:
5. 1002/cac2.12207.
6. S. Mubarik et al., “Epidemiological and sociodemographic transitions of female breast cancer
7. incidence, death, case fatality and DALYs in 21 world regions and globally, from 1990 to 2017: An
8. Age-Period-Cohort Analysis,” J. Adv. Res., vol. 37, pp. 185–196, 2022, doi: 10.1016/j.jare.2021.07.012.
9. S. M. Lima, R. D. Kehm, and M. B. Terry, “Global breast cancer incidence and mortality trends by
10. region, age-groups, and fertility patterns,” EClinicalMedicine, vol. 38, p. 100985, 2021, doi:
11. 1016/j.eclinm.2021.100985.
12. Z. Ullah, M. N. Khan, Z. U. Din, and S. Afaq, “Breast Cancer Awareness and Associated Factors
13. Amongst Women in Peshawar, Pakistan: A Cross-Sectional Study,” Breast Cancer Basic Clin. Res.,
14. vol. 15, 2021, doi: 10.1177/11782234211025346.
15. S. Hafeez, A. Ahmed, A. Z. Rashid, and M. A. Kayani, “Down-regulation of CYP1A1 expression in
16. breast cancer,” Asian Pacific J. Cancer Prev., vol. 13, no. 5, pp. 1757–1760, 2012, doi: 10.7314/AP-
17. JCP.2012.13.5.1757.
18. F. Farzaneh et al., “Analysis of CYP17, CYP19 and CYP1A1 gene polymorphisms in Iranian
19. women with breast cancer,” Asian Pacific J. Cancer Prev., vol. 17, no. SpecialIssue, pp. 23–26, 2016,
20. d’oi: 10.7314/APJCP.2016.17.
21. W. Lee and T. G. Boyer, “<1-s2.0-S0140673601070180-main.pdf>,” p. 78245, 2001.
22. G. Yang, C. Sau, W. Lai, J. Cichon, and W. Li, “BRAC1 and BRAC2 mutation and treatment
23. strategies for breast cancer,” HHS Pulic Access, vol. 344, no. 6188, pp. 1173–1178, 2015, [Online].
24. Available: http://www.ncbi.nlm.nih.gov/pubmed/28706734%0Ahttp://www.-
25. pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5505673
26. L. M. Gearhart-Serna, B. A. Mills, H. Hsu, O. M. Fayanju, K. Hoffman, and G. R. Devi,
27. “Cumulative environmental quality is associated with breast cancer incidence differentially by summary
28. stage and urbanicity,” Sci. Rep., vol. 13, no. 1, pp. 1–11, 2023, doi: 10.1038/s41598-023-45693-0.
29. A. M. Lewandowska, M. Rudzki, S. Rudzki, T. Lewandowski, and B. Laskowska, “Environmental
30. risk factors for cancer - review paper,” Ann. Agric. Environ. Med., vol. 26, no. 1, pp. 1–7, 2019, doi:
31. 26444/aaem/94299.
32. M. Furkan Ercisli, D. Kahrizi, and Z. Aziziaram, “Environmental factors affecting the risk of breast
33. cancer and the modulating role of vitamin D on this malignancy,” Cent. Asian J. Environ. Sci. Technol.
34. Innov., vol. 4, pp. 175–183, 2021.
35. M. Rodriguez and D. A. Potter, “CYP1A1 regulates breast cancer proliferation and survival,
36. ” Mol. Cancer Res., vol. 11, no. 7, pp. 780–792, 2013, doi: 10.1158/1541-7786.MCR-12-0675.
37. H. G. Sutherland et al., “Investigation of polymorphisms in genes involved in estrogen metabolism
38. in menstrual migraine,” vol. 607, pp. 36–40, 2017, doi: 10.1016/j.gene.2017.01.008.
39. Y. Li et al., “Cigarette smoking, cytochrome P4501A1 polymorphisms, and breast cancer among
40. African-American and white women,” Breast Cancer Res., vol. 6, no. 4, 2004, doi: 10.1186/bcr814.
41. G. Golmohammadzadeh, A. Mohammadpour, N. Ahangar, and M. Shokrzadeh, “Polymorphisms in
42. phase I (Cyp450) genes CYP1a1 (rs4646421), CYP1b1 (Rs1056836), CYP19a1 (Rs749292) and CYP2c8
43. (rs1058930) and their relation to risk of breast cancer: A case-control study in Mazandaran province in
44. north of Iran,” Open Access Maced. J. Med. Sci., vol. 7, no. 15, pp. 2488–2496, 2019, doi: 10.3889/o
45. amjms.2019.667.
46. M. R. Sowers, A. L. Wilson, S. R. Kardia, J. Chu, and D. S. Mcconnell, “CYP1A1 and CYP1B1
47. Polymorphisms and Their Association with Estradiol and Estrogen Metabolites in Women Who Are
48. Premenopausal and Perimenopausal,” vol. 119, pp. 44–51, 2006, doi: 10.1016/j.amjmed.2006.07.006.
49. I. Frikha, R. Frikha, M. Medhaffer, H. Charfi, F. Turki, and M. Elloumi, “Impact of CYP1A1
50. variants on the risk of acute lymphoblastic leukemia : evidence from an updated meta ‐ analysis,” 2024,
51. doi: 10.1007/s44313-024-00007-9.
52. J. Qin, J. X. Zhang, X. P. Li, B. Q. Wu, G. Bin Chen, and X. F. He, “Association between
53. the CYP1A1 A2455G polymorphism and risk of cancer: Evidence from 272 case-control studies,”
54. Tumor Biol., vol. 35, no. 4, pp. 3363–3376, 2014, doi: 10.1007/s13277-013-1443-2.
55. M. Murithi, S. Nyanjom, V. Mobegi, S. Shahin, and F. Makokha, “Association of rs4646903 and
56. rs1048943 CYP1A1 estrogen-metabolizing gene polymorphisms with estrogen receptor-positive breast
57. cancer in Kenyan women,” Arch. Biol. Sci., vol. 75, no. 1, pp. 57–67, 2023, doi:
58. 2298/ABS230115005M.
59. C.-H. Lin, M. Zahid, M.-Y. Wang, C. L. Beseler, Y.-S. Lu, and E. G. Rogan, “Estrogen-DNA
60. adduct ratios as a predictor for breast cancer risk in premenopausal Asian women,” pp. 1–11, 2022.
61. S. Q. Ibrahem, H. Q. Ahmed, and K. M. Amin, “Genetic Variations in Cytochrome P450 1A1 and
62. B1 Genes in a Cohort of Patients from Iraq Diagnosed with Breast Cancer,” Breast Cancer Basic Clin.
63. Res., vol. 15, 2021, doi: 10.1177/11782234211050727.
64. F. Zhao et al., “Discovery of breast cancer risk genes and establishment of a prediction model based
65. on estrogen metabolism regulation,” BMC Cancer, vol. 21, no. 1, pp. 1–11, 2021, doi:
66. 1186/s12885-021-07896-4.
67. F. Hamad, S. I. Mohammed, A. O. Mohamed, and D. O. A. Elmustafa, “Patients’ characteristics,
68. Cytochrome P4501A1 genetic polymorphisms and breast cancer risk in Sudanese women,” South African
69. J. Oncol., vol. 5, pp. 1–7, 2021, doi: 10.4102/sajo.v5i0.150.
70. G. KhaliliTanha, A. Barzegar, N. Nikbakhsh1, and A. Pirsaraei2, “Association of CYP1A1 M2
71. (A2455G) Polymorphism with Susceptibility to Breast Cancer in Mazandaran Province,
72. Northern Iran,” Int. J. Prev. Med., vol. 8, pp. 1–6, 2017, doi: 10.4103/ijpvm.IJPVM_57_18.
73. A. M. Francis et al., “Breast cancer susceptibility genes in estrogen metabolizing pathway in a
74. southern Indian population,” Meta Gene, vol. 19, no. October 2018, pp. 225–234, 2019, doi:
75. 1016/j.mgene.2018.12.009.
76. H. M. Naif, M. A. I. Al-Obaide, H. H. Hassani, A. S. Hamdan, and Z. S. Kalaf, “Association of
77. cytochrome CYP1A1 gene polymorphisms and tobacco smoking with the risk of breast cancer in women
78. from Iraq,” Front. Public Heal., vol. 6, no. April, pp. 1–7, 2018, doi: 10.3389/fpubh.2018.00096.
79. S. L. Humberto Parada Jr, PhD a,*, Susan E. Steck, PhD b, Rebecca J. Cleveland, PhD c, and M.
80. D. Teitelbaum, PhD d, Alfred I. Neugut, MD PhD e, f, Regina M. Santella, PhD g, and P. a Gammon,
81. “Genetic polymorphisms of phase I metabolizing enzyme genes, their interaction with lifetime grilled and
82. smoked meat intake, and breast cancer incidence,” HHS public access, vol. 27, no. 3, pp. 1–17, 2017, doi:
83. 1016/j.annepidem.2016.11.005.
84. A. García-Martínez, B. Gamboa-Loira, M. E. Tejero, A. Sierra-Santoyo, M. E. Cebrián, and L.
85. López-Carrillo, “CYP1A1, CYP1B1, GSTM1 and GSTT1 genetic variants and breast cancer risk in
86. Mexican women,” Salud Publica Mex., vol. 59, no. 5, pp. 540–547, 2017, doi: 10.21149/8527.
87. M. Ghisari, M. Long, D. M. Røge, J. Olsen, and E. C. Bonefeld-Jørgensen, “Polymorphism in
88. xenobiotic and estrogen metabolizing genes, exposure to perfluorinated compounds and subsequent breast
89. cancer risk: A nested case-control study in the Danish National Birth Cohort,” Environ. Res., vol. 154,
90. no. February, pp. 325–333, 2017, doi: 10.1016/j.envres.2017.01.020.
91. H. A. Mutar, “Association of CYP1A1 gene polymorphism with breast cancer incidence,” Int. J.
92. Res. Pharm. Sci., vol. 8, no. 4, pp. 635–641, 2017.
93. P. Bab, R. M. Sc, Z. T. Fard, D. Ph, and N. N. P. D, “Original Article Association of CYP1A1
94. IIe462Val ( rs1048943 ) Polymorphism with Breast Cancer in Iranian Women,” vol. 3, no. 4, pp.
95. –220, 2017.
96. I. Amrani et al., “Lack of association between CYP1A1 M2 and M4 polymorphisms and breast
97. carcinoma in Jordanian women: A case-control study,” Asian Pacific J. Cancer Prev., vol. 17, no. 1, pp.
98. –393, 2016, doi: 10.7314/APJCP.2016.17.1.387.
99. C. B. Martins de Oliveira, C. Cardoso-Filho, L. S. Bossi, G. J. Lourenço, M. S. Costa-Gurgel, and
100. C. S. Passos Lima, “Association of CYP1A1 A4889G and T6235C polymorphisms with the risk of
101. sporadic breast cancer in Brazilian women,” Clinics, vol. 70, no. 10, pp. 680–685, 2015, doi: 10.6061/-
102. clinics/2015(10)04.
103. M. Ghisari, H. Eiberg, M. Long, and E. C. Bonefeld-Jørgensen, “Polymorphisms in Phase i and
104. Phase II genes and breast cancer risk and relations to persistent organic pollutant exposure: A case-con-
105. trol study in Inuit women,” Environ. Heal. A Glob. Access Sci. Source, vol. 13, no. 1, pp. 1–14, 2014,
106. doi: 10.1186/1476-069X-13-19.
107. H. Saadatian, J. Gharesouran, V. Montazeri, S. A. Mohammadi, and S. M. Mohaddes Ardabili,
108. “Polymorphism of the cytochrome P-450 1A1 (A2455G) in women with breast cancer in Eastern Azer-
109. baijan, Iran,” Iran. J. Basic Med. Sci., vol. 17, no. 3, pp. 227–230, 2014.
110. O. C. Martínez-ramírez, R. Pérez-morales, C. Castro, A. Flores-díaz, and K. E. Soto-cruz, “Poly-
111. morphisms of catechol estrogens metabolism pathway genes and breast cancer risk in Mexican women,”
112. The Breast, vol. 22, no. 3, pp. 335–343, 2013, doi: 10.1016/j.breast.2012.08.004.
113. Q. Wang, H. Li, P. Tao, Y. Wang, P. Yuan, and C. Yang, “and COMT Polymorphisms , and Breast
114. Cancer : A Case – Control Study in Southwestern China,” vol. 30, no. 8, pp. 585–595, 2011, doi:
115. 1089/dna.2010.1195.
116. M. Moreno-Galván, N. E. Herrera-González, V. Robles-Pérez, J. C. Velasco-Rodríguez, R.
117. Tapia-Conyer, and E. Sarti, “Impact of CYP1A1 and COMT genotypes on breast cancer risk in Mexican
118. women: A pilot study,” Int. J. Biol. Markers, vol. 25, no. 3, pp. 157–163, 2010, doi:
119. 1177/172460081002500306.
120. Marie et al, “Genetic polymorphisms in phase i and phase II enzymes and breast cancer risk associ-
121. ated with menopausal hormone therapy in postmenopausal women,” Breast Cancer Res. Treat., vol. 119,
122. no. 2, pp. 463–474, 2010, doi: 10.1007/s10549-009-0407-0.
123. L. Delort, S. Satih, F. Kwiatkowski, Y. J. Bignon, and D. J. Bernard-Gallon, “Evaluation of breast
124. cancer risk in a multigenic model including low penetrance genes involved in xenobiotic and estrogen
125. metabolisms,” Nutr. Cancer, vol. 62, no. 2, pp. 243–251, 2010, doi: 10.1080/01635580903305300.
126. D. Surekha, K. Sailaja, D. N. Rao, T. Padma, and D. Raghunadharao, “ASSOCIATION OF
127. CYP1A1 * 2 POLYMORPHISMS WITH BREAST CANCER RISK : A CASE CONTROL STUDY
128. ABSTRACT,” pp. 13–20, 2009, doi: 10.4103/0019-5359.4907.
129. N. Shimada et al., “Genetic polymorphisms in estrogen metabolism and breast cancer risk in
130. case-control studies in Japanese, Japanese Brazilians and non-Japanese Brazilians,” J. Hum. Genet., vol.
131. , no. 4, pp. 209–215, 2009, doi: 10.1038/jhg.2009.13.
132. C. Justenhoven et al., “Breast cancer: A candidate gene approach across the estrogen metabolic
133. pathway,” Breast Cancer Res. Treat., vol. 108, no. 1, pp. 137–149, 2008, doi:
134. 1007/s10549-007-9586-8.
135. Shin A, Kang D, Choi JY, Lee KM, Park SK, and Noh DY, “Cytochrome P450 1A1 CYP1a1
136. polymorphisms and breast cancer risk in Korean women,” Exp. Mol. Med., vol. 39, no. 3, pp. 361–366,
137. P. Sillanpää et al., “CYP1A1 and CYP1B1 genetic polymorphisms, smoking and breast cancer risk
138. in a Finnish Caucasian population,” Breast Cancer Res. Treat., vol. 104, no. 3, pp. 287–297, 2007, doi:
139. 1007/s10549-006-9414-6.
140. V. Singh, N. Rastogi, A. Sinha, A. Kumar, N. Mathur, and M. P. Singh, “A study on the association
141. of cytochrome-P450 1A1 polymorphism and breast cancer risk in north Indian women,” Breast Cancer
142. Res. Treat., vol. 101, no. 1, pp. 73–81, 2007, doi: 10.1007/s10549-006-9264-2.
143. S. M. Boyapati, O. S. Xiao, Y. T. Gao, Q. Cai, F. Jin, and W. Zheng, “Polymorphisms in CYP1A1
144. and breast carcinoma risk in a population-based case-control study of Chinese women,” Cancer, vol. 103,
145. no. 11, pp. 2228–2235, 2005, doi: 10.1002/cncr.21056.
146. S. M. Boyapati, O. S. Xiao, Y. T. Gao, Q. Cai, F. Jin, and W. Zheng, “Polymorphisms in CYP1A1
147. and breast carcinoma risk in a population-based case-control study of Chinese women,” Cancer, vol. 103,
148. no. 11, pp. 2228–2235, 2005, doi: 10.1002/cncr.21056.
149. L. A. Hefler et al., “Estrogen-metabolizing gene polymorphisms in the assessment of breast carcino-
150. ma risk and fibroadenoma risk in Caucasian women,” Cancer, vol. 101, no. 2, pp. 264–269, 2004, doi:
151. 1002/cncr.20361.
152. Y. Miyoshi, Y. Takahashi, C. Egawa, and S. Noguchi, “Breast cancer risk associated with CYP1A1
153. genetic polymorphisms in Japanese women,” Breast J., vol. 8, no. 4, pp. 209–215, 2002, doi:
154. 1046/j.1524-4741.2002.08404.x.
155. C. S. Huang, C. Y. Shen, K. J. Chang, S. M. Hsu, and H. D. Chern, “Cytochrome P4501A1 poly-
156. morphism as a susceptibility factor for breast cancer in postmenopausal Chinese women in Taiwan,” Br.
157. J. Cancer, vol. 80, no. 11, pp. 1838–1843, 1999, doi: 10.1038/sj.bjc.6690608.
158. D. A. Ralph et al., “Age-specific association of steroid hormone pathway gene polymorphisms with
159. breast cancer risk,” Cancer, vol. 109, no. 10, pp. 1940–1948, 2007, doi: 10.1002/cncr.22634.
160. D. Grimm, “Recent advances in breast cancer research.,” Int. J. Mol. Sci., vol. 24, pp. 1–9, 2023,
161. doi: https://doi.org/10.3390/ijms241511990.
162. S. Jahandoost, P. Farhanghian, and S. Abbasi, “The Effects of Sex Protein Receptors and Sex
163. Steroid Hormone Gene Polymorphisms on Breast Cancer Risk,” J. Natl. Med. Assoc., vol. 109, no. 2, pp.
164. –138, 2017, doi: 10.1016/j.jnma.2017.02.003.
165. A. Abhishek, N. G. Ansari, V. Singh, R. J. Sinha, P. Mishra, and A. Mishra, “Genetic susceptibility
166. of CYP1A1 gene and risk of pesticide exposure in prostate cancer,” Cancer Biomarkers, vol. 29, no. 4,
167. pp. 429–440, 2020, doi: 10.3233/CBM-190636.

License

Copyright (c) 2026 Syeda Qudsia Hijab